Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-289

completely disagree, clearly Mason knows a thing or two about clinical trials and data. He's got every right to post on any thread he finds interesting..
I find it dangerous to suggest we shareholders should not do any further research or analysis, or be asking questions. As others have suggested.
if Jase99 chooses to debunk said poster, and in fact, provide further clarity of IMUs position then he has every right too. I applaud this approach rather than repeat the same information, beat the same drum over and over to ad nauseam.

I draw an issue with holders who, out of fear of their own hip pocket, choose to steamroll over others because it doesn't suit their agenda or financial objectives .

there is too much policing and silencing of these forums.